TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
LTRN

Lantern Pharma Inc

Healthcare · Biotechnology

0.64$ -3.2% vs. previous close Closing price · As of: Nov 2, 2026

Ownership

Ownership Structure

Who owns Lantern Pharma Inc (LTRN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 71.6% of the shares are freely tradable; institutional investors hold 14.2%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 14.2%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 17.2%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 71.6%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 3.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 15Mio.

Largest Shareholders

Institutions

Institutions LTRN
Name Stake (%) Shares Change (%) Date
Empery Asset Management, LP 5.64 842,669 +0.0 06/30/2026
CM Management, LLC 3.35 500,000 +100.0 06/30/2026
Vanguard Capital Management, LLC 2.85 425,118 +28.0 06/30/2026
Renaissance Technologies Corp 1.95 291,039 +150.9 06/30/2026
BIOS CAPITAL MANAGEMENT, LP 1.67 249,397 -71.1 06/30/2026
Geode Capital Management, LLC 0.69 102,819 -7.9 06/30/2026
Vanguard Fiduciary Trust Co 0.33 49,950 +0.7 06/30/2026

Funds

Funds LTRN
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.27 338,385 +0.0 09/30/2026
Abante Quant Value FI 0.36 53,373 +50.8 08/31/2026
Fidelity Extended Market Index 0.33 49,366 +9.7 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?